Senseonics(US:SENS)2026-03-02 21:37Financial Performance - Total revenue for the year ended December 31, 2025, was $35.257 million, a 56.8% increase from $22.472 million in 2024[511] - Gross profit for 2025 was $15.763 million, compared to $533,000 in 2024, indicating a significant improvement in profitability[511] - The net loss for 2025 was $69.113 million, a decrease from a net loss of $78.616 million in 2024, reflecting better operational performance[511] - Basic net loss per common share improved to $(1.66) in 2025 from $(2.50) in 2024, suggesting better performance on a per-share basis[511] - The net loss for 2025 was $69,113,000, an improvement from a net loss of $78,616,000 in 2024, resulting in a net loss per share of $(1.66) compared to $(2.50) in the previous year[589] Revenue Sources - Revenue from the United States accounted for 79.2% of total revenue in 2025, up from 68.0% in 2024, while revenue from outside the United States was 20.8% in 2025, down from 32.0% in 2024[579] - Sales to Ascensia represented 53% of total revenue in 2025, a decrease from 82% in 2024[581] - Consignment sales accounted for 41% of total revenue in 2025, significantly up from 15% in 2024[582] - Revenue from Ascensia for 2025 was $18.2 million, a slight decrease from $18.5 million in 2024[673] Expenses - Research and development expenses decreased to $31.592 million in 2025 from $41.144 million in 2024, showing a focus on cost management[511] - Selling, general and administrative expenses increased to $52.508 million in 2025 from $34.231 million in 2024, indicating higher operational costs[511] - Advertising expenses of $11.2 million for the year ended December 31, 2025, which were not significant in 2024[566] - Sales and marketing expenses significantly increased to $22,785,000 in 2025 from $7,268,000 in 2024, marking a rise of about 213.5%[686] - General and administrative expenses rose to $29,723,000 in 2025 from $26,963,000 in 2024, an increase of about 10.3%[686] Cash and Liquidity - Cash and cash equivalents decreased to $40.234 million as of December 31, 2025, down from $74.597 million in 2024, raising concerns about liquidity[509] - The company anticipates requiring additional liquidity to continue operations over the next twelve months, indicating potential financial challenges ahead[501] - The company had unrestricted cash, cash equivalents, and marketable securities totaling $94.0 million as of December 31, 2025[527] - The Company had cash, cash equivalents, and restricted cash totaling $40.5 million as of December 31, 2025, down from $74.9 million in 2024[544] - The fair value of cash and cash equivalents, including money market funds, was $33,624,000 as of December 31, 2025, down from $70,613,000 in 2024[681] Assets and Liabilities - Total assets increased to $126.269 million in 2025 from $100.438 million in 2024, reflecting growth in the company's asset base[509] - Total liabilities decreased to $65.223 million in 2025 from $79.337 million in 2024, indicating improved financial health[509] - Total accrued expenses and other current liabilities rose to $20,289,000 in 2025 from $15,506,000 in 2024, with notable increases in sales and marketing services and professional services[600] Financing Activities - The company generated $78.2 million in net cash from financing activities in 2025, compared to $26.8 million in 2024[518] - The Company raised approximately $2.4 million from the sale of 334,330 shares under the Sales Agreement with TD Cowen, after deducting sales commissions and offering expenses[532] - The Public Offering on May 15, 2025, generated gross proceeds of $57.5 million from the sale of 5,000,000 shares at $10.00 per share, with net proceeds of approximately $52.1 million after expenses[533] - The Company received approximately $20.1 million in net proceeds from a Private Placement with Abbott Laboratories for 2,026,963 shares at the Public Offering Price[533] - The Equity Distribution Agreement with Goldman Sachs allowed the Company to sell shares with an aggregate offering price of up to $106.6 million, later amended to $55.0 million, resulting in approximately $30.8 million in net proceeds from the sale of 2,006,528 shares[535] Stock and Equity - A reverse stock split of 1-for-20 was executed on October 17, 2025, reducing the total number of authorized shares from 1.4 billion to 70 million[523] - The Company had 41,265,778 shares of common stock outstanding as of December 31, 2025, compared to 29,767,561 shares as of December 31, 2024[626] - The Company had no shares of preferred stock outstanding as of December 31, 2025, following the conversion of Series B Preferred Stock into common stock[627] - The Company issued $82.0 million in senior convertible notes in July 2019, with an initial conversion rate of 37.88 shares per $1,000 principal amount[618] Inventory and Cost of Goods Sold - Total inventory increased to $6,703,000 in 2025 from $4,421,000 in 2024, with a significant reduction in cost of sales related to obsolete inventory, amounting to $0.7 million in 2025 compared to $4.3 million in 2024[593] - Cost of goods sold decreased to $19,494,000 in 2025 from $21,939,000 in 2024, reflecting a reduction of approximately 11.1%[686] Agreements and Contracts - The Company has a management services agreement for 10 years to support patient access to the Eversense system, involving contracting healthcare professionals[540] - The company executed a Master Asset Purchase Agreement with Ascensia on December 31, 2025, acquiring certain U.S. commercial assets[675] Other Financial Metrics - The accumulated deficit reached $1.0 billion as of December 31, 2025[527] - The credit loss reserve increased to $1.3 million as of December 31, 2025, compared to $0.3 million in 2024[548] - Estimated warranty liabilities increased to $448,000 at the end of 2025, up from $406,000 at the end of 2024, with provisions for warranties during the period totaling $408,000[556] - The Company has gross federal NOL carryforwards of $791.3 million and state NOL carryforwards of $134.9 million as of December 31, 2025[665]